Issue navigation
Volume 8, Issue 6, October 2022
EDITORIAL
Prevention is still the key to success
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 537–538, https://doi.org/10.1093/ehjcvp/pvac046
ORIGINAL ARTICLES
An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 539–548, https://doi.org/10.1093/ehjcvp/pvab052
Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 549–556, https://doi.org/10.1093/ehjcvp/pvab053
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 557–567, https://doi.org/10.1093/ehjcvp/pvac001
Cardiovascular risks associated with calcium supplementation in patients with osteoporosis: a nationwide cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 568–577, https://doi.org/10.1093/ehjcvp/pvab054
Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 578–586, https://doi.org/10.1093/ehjcvp/pvab064
A dose–response relationship of renin–angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 587–599, https://doi.org/10.1093/ehjcvp/pvac002
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 600–608, https://doi.org/10.1093/ehjcvp/pvac008
EDITORIAL
Comment on Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 609–610, https://doi.org/10.1093/ehjcvp/pvac012
ORIGINAL ARTICLES
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 611–621, https://doi.org/10.1093/ehjcvp/pvac015
The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 622–632, https://doi.org/10.1093/ehjcvp/pvac025
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 6, October 2022, Pages 633–643, https://doi.org/10.1093/ehjcvp/pvac021
